BioWorld

Feb. 23, 2010

Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal

Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today) Read More

FDA Raises Endpoint Concerns in Study of Salix Liver Drug

Blocking Backup Pathway Could Prevent Glioblastoma Comeback

New Money Scarce, so ITS Founders Chip in $13.4M

Icahn Makes Move as Genzyme Looks for Good News in 2010

White House Health Bill Adopts 12 Years for FOBs

NIH Stem Cell Definition Change 'Hugely Important'

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...